Copyright Reports & Markets. All rights reserved.

Global Spinal Muscular Atrophy (SMA) Treatment Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Spinal Muscular Atrophy (SMA) Treatment Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Type I Spinal Muscular Atrophy (SMA)
      • 1.4.3 Type II Spinal Muscular Atrophy (SMA)
      • 1.4.4 Type III Spinal Muscular Atrophy (SMA)
    • 1.5 Market by Application
      • 1.5.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Application: 2020 VS 2026
      • 1.5.2 Hospitals
      • 1.5.3 Ambulatory Surgical Centers
      • 1.5.4 Diagnostic Centers
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Spinal Muscular Atrophy (SMA) Treatment Market Perspective (2015-2026)
    • 2.2 Spinal Muscular Atrophy (SMA) Treatment Growth Trends by Regions
      • 2.2.1 Spinal Muscular Atrophy (SMA) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Spinal Muscular Atrophy (SMA) Treatment Historic Market Share by Regions (2015-2020)
      • 2.2.3 Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Spinal Muscular Atrophy (SMA) Treatment Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Spinal Muscular Atrophy (SMA) Treatment Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Market Size
      • 3.1.1 Global Top Spinal Muscular Atrophy (SMA) Treatment Players by Revenue (2015-2020)
      • 3.1.2 Global Spinal Muscular Atrophy (SMA) Treatment Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Spinal Muscular Atrophy (SMA) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Spinal Muscular Atrophy (SMA) Treatment Market Concentration Ratio
      • 3.2.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy (SMA) Treatment Revenue in 2019
    • 3.3 Spinal Muscular Atrophy (SMA) Treatment Key Players Head office and Area Served
    • 3.4 Key Players Spinal Muscular Atrophy (SMA) Treatment Product Solution and Service
    • 3.5 Date of Enter into Spinal Muscular Atrophy (SMA) Treatment Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Spinal Muscular Atrophy (SMA) Treatment Historic Market Size by Type (2015-2020)
    • 4.2 Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Type (2021-2026)

    5 Spinal Muscular Atrophy (SMA) Treatment Breakdown Data by Application (2015-2026)

    • 5.1 Global Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)
    • 5.2 Global Spinal Muscular Atrophy (SMA) Treatment Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 6.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in North America (2019-2020)
    • 6.3 North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 6.4 North America Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 7.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Europe (2019-2020)
    • 7.3 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 7.4 Europe Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    8 China

    • 8.1 China Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 8.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in China (2019-2020)
    • 8.3 China Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 8.4 China Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    9 Japan

    • 9.1 Japan Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 9.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Japan (2019-2020)
    • 9.3 Japan Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 9.4 Japan Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    10 Southeast Asia

    • 10.1 Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 10.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Southeast Asia (2019-2020)
    • 10.3 Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 10.4 Southeast Asia Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    11 India

    • 11.1 India Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 11.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in India (2019-2020)
    • 11.3 India Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 11.4 India Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    12 Central & South America

    • 12.1 Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size (2015-2020)
    • 12.2 Spinal Muscular Atrophy (SMA) Treatment Key Players in Central & South America (2019-2020)
    • 12.3 Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size by Type (2015-2020)
    • 12.4 Central & South America Spinal Muscular Atrophy (SMA) Treatment Market Size by Application (2015-2020)

    13 Key Players Profiles

    • 13.1 Pfizer
      • 13.1.1 Pfizer Company Details
      • 13.1.2 Pfizer Business Overview and Its Total Revenue
      • 13.1.3 Pfizer Spinal Muscular Atrophy (SMA) Treatment Introduction
      • 13.1.4 Pfizer Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020))
      • 13.1.5 Pfizer Recent Development
    • 13.2 Isis Pharmaceuticals
      • 13.2.1 Isis Pharmaceuticals Company Details
      • 13.2.2 Isis Pharmaceuticals Business Overview and Its Total Revenue
      • 13.2.3 Isis Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Introduction
      • 13.2.4 Isis Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
      • 13.2.5 Isis Pharmaceuticals Recent Development
    • 13.3 Biogen Idec
      • 13.3.1 Biogen Idec Company Details
      • 13.3.2 Biogen Idec Business Overview and Its Total Revenue
      • 13.3.3 Biogen Idec Spinal Muscular Atrophy (SMA) Treatment Introduction
      • 13.3.4 Biogen Idec Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
      • 13.3.5 Biogen Idec Recent Development
    • 13.4 Boehringer Ingelheim
      • 13.4.1 Boehringer Ingelheim Company Details
      • 13.4.2 Boehringer Ingelheim Business Overview and Its Total Revenue
      • 13.4.3 Boehringer Ingelheim Spinal Muscular Atrophy (SMA) Treatment Introduction
      • 13.4.4 Boehringer Ingelheim Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
      • 13.4.5 Boehringer Ingelheim Recent Development
    • 13.5 F. Hoffmann-La Roche
      • 13.5.1 F. Hoffmann-La Roche Company Details
      • 13.5.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue
      • 13.5.3 F. Hoffmann-La Roche Spinal Muscular Atrophy (SMA) Treatment Introduction
      • 13.5.4 F. Hoffmann-La Roche Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
      • 13.5.5 F. Hoffmann-La Roche Recent Development
    • 13.6 Regeneron Pharmaceuticals
      • 13.6.1 Regeneron Pharmaceuticals Company Details
      • 13.6.2 Regeneron Pharmaceuticals Business Overview and Its Total Revenue
      • 13.6.3 Regeneron Pharmaceuticals Spinal Muscular Atrophy (SMA) Treatment Introduction
      • 13.6.4 Regeneron Pharmaceuticals Revenue in Spinal Muscular Atrophy (SMA) Treatment Business (2015-2020)
      • 13.6.5 Regeneron Pharmaceuticals Recent Development

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
        • 15.1.2 Data Source
      • 15.2 Disclaimer

      This report focuses on the global Spinal Muscular Atrophy (SMA) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Spinal Muscular Atrophy (SMA) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Pfizer
      Isis Pharmaceuticals
      Biogen Idec
      Boehringer Ingelheim
      F. Hoffmann-La Roche
      Regeneron Pharmaceuticals
      ...

      Market segment by Type, the product can be split into
      Type I Spinal Muscular Atrophy (SMA)
      Type II Spinal Muscular Atrophy (SMA)
      Type III Spinal Muscular Atrophy (SMA)
      Market segment by Application, split into
      Hospitals
      Ambulatory Surgical Centers
      Diagnostic Centers
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Spinal Muscular Atrophy (SMA) Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Spinal Muscular Atrophy (SMA) Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by type, market and key regions.

      In this study, the years considered to estimate the market size of Spinal Muscular Atrophy (SMA) Treatment are as follows:
      History Year: 2015-2019
      Base Year: 2019
      Estimated Year: 2020
      Forecast Year 2020 to 2026
      For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now